2026 - Passed
Colorado S.B. 26-006
  • Requires health insurers and Colorado Medicaid to treat FDA-approved non-opioid pain medications at least as favorably as opioids by limiting prior authorization and step therapy, ensuring non-opioid alternatives are available, and prohibiting higher cost-sharing.
  • Aims to promote non-opioid pain management by removing financial and administrative barriers.
2025 - Introduced
Georgia H.B. 326
  • Prohibits practices that disadvantage or discourage the use of non-opioid drugs relative to opioids in state employees' health insurance and benefit plans.
2025 - Introduced
Kansas H.B. 2364
  • Requires state health programs to cover non-opioid pain medications without requiring patients to try opioids first and without less favorable coverage or higher cost-sharing than opioids.
  • Prohibits formularies from disadvantaging FDA-approved non-opioid pain treatments through stricter utilization controls or tier placement.
2026 - Introduced
Missouri H.B. 1680
  • Requires commercial plans to cover non-opioid medications for acute pain without disadvantaging them compared to opioids.
2026 - Introduced
Missouri S.B. 1024
Limits initial opioid prescriptions for acute pain in Missouri to a seven-day supply, requires practitioners to discuss risks, alternatives, and dosing options with patients, and mandates documentation if a longer supply is medically necessary.
2026 - Introduced
Missouri S.B. 902/S.B. 1340/S.B. 1449/S.B. 841/H.B. 2642/S.B. 878/ S.B. 1350
  • Requires Missouri commercial plans to cover non-opioid medications for acute pain without denying coverage in favor of opioids, mandating prior opioid use, or imposing utilization controls, such as higher cost-sharing or step therapy, or prior authorization when prescribed.
2026 - Introduced
New Jersey A1821/S.B. 4283
  • Prohibits health insurers from denying coverage of non-opioid prescription drugs in favor of opioid prescription drugs.
2025 - Introduced
Oklahoma H.B.1416
  • Ensures that a non-opioid drug approved by the FDA is not disadvantaged or discouraged with respect to coverage relative to an opioid for the treatment or management of pain on the state preferred drug list.
2026 - Introduced
Pennsylvania H.B. 2060/S.B. 1196
  • Requires Medicaid and commercial insurers to provide pain parity by ensuring FDA-approved non opioid drugs are not disadvantaged in coverage, cost sharing, or utilization controls compared with opioids, applying upon FDA approval.
2026 - Introduced
Rhode Island S.B. 3022/H.B. 2060
  • Requires health insurers to provide equal access to FDA-approved non-opioid pain medications, eliminating prior authorization and step therapy requirements that currently give opioids a prescribing advantage.
2024 - Passed
Tennessee H.B.37
  • Aligns group health insurance plans providing coverage for state employees with Medicaid non-opioid parity policy, ensuring reimbursement of all FDA-approved non-opioid drugs.
2026 - Passed
Utah Senate Concurrent Resolution 5
  • Directs the state employee health plan to include at least one clinically appropriate non-opioid prescription alternative for each covered opioid.
  • Prohibits health plan from establishing more restrictive or extensive utilization controls for non-opioid treatments than the least restrictive or extensive utilization control for any opioid.